Insights

Gathering insights about Apto…

Similar companies to Apto

Apto Tech Stack

Apto uses 8 technology products and services including Criteo, Cloudflare Web Optimizations, Facebook Pixel, and more. Explore Apto's tech stack below.

Criteo
Advertising
Cloudflare Web Optimizations
Analytics
Facebook Pixel
Analytics
cdnjs
Content Delivery Network
Cloudflare CDN
Content Delivery Network
LottieFiles
Design
Google Fonts API
Font Scripts
jQuery
Javascript Libraries

Media & News

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and 160 mg TUS with TUS+VEN+AZA triplet Composite complete response (CRc) rate in evaluable patients across all dosing groups was 86.2% MRD-negativity in patients who achieved a CR/CRh response was 86.4% AML patients with diverse genetics, including TP53-mutated, complex karyotypes, and unmutated FLT3, safely achieved responses and MRD negativity SAN DIEGO and TORONTO, June 15, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed AML patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) was presented yesterday in an oral presentation at the European Hematology Association Congress (EHA 2026) in Stockholm, Sweden. The TUS+VEN+AZA triplet is being developed as a mutation agnostic frontline therapy to treat large, mutationally unrestricted and diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.
Jun 15, 2026 | www.globenewswire.com
Aptose Reports First Quarter 2026 Results
SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. “Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, and we're pleased that an update of our TUS+VEN+AZA triplet clinical data has been selected for an oral presentation at the upcoming EHA2026 Congress in June,” said William G.
May 13, 2026 | www.globenewswire.com
Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO)'s share price passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of C$2.21 and traded as high as C$2.25. Aptose Biosciences shares last traded at C$2.25, with a volume of 3,066 shares changing hands. Aptose
Mar 31, 2026 | www.defenseworld.net
Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO)'s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$2.19 and traded as high as C$2.26. Aptose Biosciences shares last traded at C$2.26, with a volume of 781 shares trading hands. Analyst
Jan 24, 2026 | www.defenseworld.net
Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose's Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Population
Dec 06, 2025 | www.globenewswire.com
Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Should You Sell?
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO) crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of C$1.89 and traded as high as C$2.32. Aptose Biosciences shares last traded at C$2.32, with a volume of 4,636 shares. Analyst Ratings Changes Separately, Alliance
Dec 03, 2025 | www.defenseworld.net
Aptose Announces Auditor Not Standing for Re-Appointment
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company's 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two fiscal quarters of 2025.
Apr 23, 2025 | www.globenewswire.com

Apto's Email Address Formats

Apto uses at least 1 format(s):

Apto Email Formats	Example	Percentage
First.Last@apto.vc	John.Doe@apto.vc	100%

Frequently Asked Questions

Where is Apto's headquarters located?

Apto's main headquarters is located at 2561 Avenue Dos Autonomistas Osasco, São Paulo 06090-020 Brazil. The company has employees across 4 continents, including South AmericaEuropeAsia.

What is Apto's stock symbol?

Apto is a publicly traded company; the company's stock symbol is APTO.

What is Apto's official website and social media links?

Apto's official website is apto.vc and has social profiles on LinkedIn.

What is Apto's SIC code NAICS code?

Apto's SIC code is 4899 - Communications Services, Not Elsewhere Classified NAICS code is 425 - Wholesale Electronic Markets and Agents and Brokers.

How many employees does Apto have currently?

As of May 2026, Apto has approximately 37 employees across 4 continents, including South AmericaEuropeAsia. Key team members include Founder & Ceo: A. F.Project Manager / Business Analyst: M. P.Growth Marketing Manager: A. R.. Explore Apto's employee directory with LeadIQ.

What industry does Apto belong to?

Apto operates in the Internet Marketplace Platforms industry.

What technology does Apto use?

Apto's tech stack includes CriteoCloudflare Web OptimizationsFacebook PixelcdnjsCloudflare CDNLottieFilesGoogle Fonts APIjQuery.

What is Apto's email format?

Apto's email format typically follows the pattern of First.Last@apto.vc. Find more Apto email formats with LeadIQ.

When was Apto founded?

Apto was founded in 2015.

Apto

Q: What is Apto's official website and social media links?

Apto's official website is apto.vc. Apto has social profiles on LinkedIn.

Q: How many employees does Apto have currently?

Apto has approximately 37 employees.

Q: What technology does Apto use?

Apto's tech stack includes Google Search Console, TikTok Pixel, React, Open Graph, Google Tag Manager.

Q: What is Apto's NAICS code?

Apto's NAICS code is 425 (Wholesale Electronic Markets and Agents and Brokers).

Internet Marketplace PlatformsSão Paulo, Brazil11-50 Employees

A centralized platform that connects all participants involved in real estate launches, linking buyers with developers, construction firms, brokerages, and CRM providers. Its network spans property buyers, construction companies, developers, real estate agencies, online brokers, and CRM-focused agencies. The company aims to increase user autonomy by offering more intuitive campaigns, novel digital offerings, and personalized service.

Based in Osasco in the São Paulo region, Brazil, Apto operates within the Internet marketplace platforms sector. It positions itself as a facilitator that streamlines collaboration among diverse real estate stakeholders around launches. With a small to mid-sized team, it serves the Brazilian market by enabling autonomous, personalized engagement throughout the launch process.

Company Overview

Headquarters: 2561 Avenue Dos Autonomistas Osasco, São Paulo 06090-020 Brazil
Website: apto.vc
SIC Code: 4899 - Communications Services, Not Elsewhere Classified
Stock Symbol: APTO
NAICS Code: 425 - Wholesale Electronic Markets and Agents and Brokers
Founded: 2015
Employees: 11-50

Media & News

Funding & Financials

$1M
Apto's revenue is estimated to be in the range of $1M

Funding & Financials

$1M
Apto's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Apto

CoStar Group

LoopNet

Real Capital Analytics

Buildout

SharpLaunch

RealMassive

Biproxi

Apto Tech Stack

Media & News

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

Aptose Reports First Quarter 2026 Results

Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?

Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Should You Sell?

Aptose Announces Auditor Not Standing for Re-Appointment

Apto's Email Address Formats

Frequently Asked Questions

Where is Apto's headquarters located?

What is Apto's stock symbol?

What is Apto's official website and social media links?

What is Apto's SIC code NAICS code?

How many employees does Apto have currently?

What industry does Apto belong to?

What technology does Apto use?

What is Apto's email format?

When was Apto founded?

Apto

Company Overview

Media & News

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

Aptose Reports First Quarter 2026 Results

Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?